ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

1:00PM-3:00PM: Abstract Number: 1289

Evaluating Peri–operative Preferences of Bariatric Surgeons in the Management of Immunosuppressive Therapy During Bariatric Surgery

Measures and Measurement of Healthcare Quality Poster

1:00PM-3:00PM: Abstract Number: 1568

Evaluation for Allogeneic Hematopoietic Stem Cell Transplant Indications and Eligibility in a Prospective Cohort of Patients with VEXAS

Vasculitis – Non-ANCA-Associated and Related Disorders Poster II

1:00PM-3:00PM: Abstract Number: 1182

Evaluation of Efficacy, Immunogenicity, and Toxicity of a Novel Drug Candidate for Scleroderma-associated Interstitial Lung Disease

Systemic Sclerosis and Related Disorders – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1309

Evaluation of Preference and Efficacy in the Treatment of Glucocorticoid-induced Osteoporosis in Patients with Autoimmune Diseases Receiving Zoledronic Acid

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

1:00PM-3:00PM: Abstract Number: 1459

Evolution of Subjective Cognitive Impairment Overtime in SLE Patients: Bayesian Longitudinal Item Response Theory Modelling

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1123

Excess of Rare Deleterious Variants Within JAK-STAT Pathway – Related Genes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease

Genetics, Genomics and Proteomics Poster

1:00PM-3:00PM: Abstract Number: 1164

Expanded CD8+ T Cell Clones from HLA-B*27-positive Patients with Spondyloarthritis Show Signs of Antigen-experience

Spondyloarthritis Including PsA – Basic Science Poster

1:00PM-3:00PM: Abstract Number: 1542

Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry

Systemic Sclerosis and Related Disorders – Clinical Poster II

1:00PM-3:00PM: Abstract Number: 1334

Exploring Canadian Patient Experiences of Living with Lupus Nephritis (LN)

Patient Outcomes, Preferences, and Attitudes Poster II

1:00PM-3:00PM: Abstract Number: 1462

Exploring the Potential of Urine: Serum Fractional Excretion Ratios as Disease Biomarkers in Active Lupus Nephritis

SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

1:00PM-3:00PM: Abstract Number: 1265

External Validation of a Giant Cell Arteritis Probability Score (GCAPS) to Risk Stratify GCA Referrals: Experience from a United Kingdom Fast Track Clinic

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1361

Factors Associated with Medication-Free Remission in Juvenile Dermatomyositis

Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease

1:00PM-3:00PM: Abstract Number: 1235

Fibroblast Activation in Psoriasis Patients Assessed by 68Ga-FAPI-04 PET-CT Is Associated with Progression to Psoriatic Arthritis

Imaging of Rheumatic Diseases Poster

1:00PM-3:00PM: Abstract Number: 1197

Folic Acid and Methotrexate Use and Their Association with COVID-19 Diagnosis and Mortality: An Analysis from the UK Biobank

Epidemiology and Public Health Poster II

1:00PM-3:00PM: Abstract Number: 1322

Follow up of Incidentally Noted Vertebral Compression Fractures

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].